Chiome Bioscience’s Proprietary ADLib(R) System Generates Diverse, High-Affinity Antibody Libraries in Only 2 Weeks

TOKYO--(Marketwire - June 02, 2009) - Chiome Bioscience, a privately held therapeutic antibody drug-development company, announced today enhancements to its proprietary ADLib® System for rapidly generating Rx Ab (therapeutic antibody) libraries. Features and benefits of the ADLib® System include:

(1) Generates diverse antibodies in only 2 weeks (not months), from which target-specific monoclonal Abs (mAbs) may be easily selected using antigens conjugated to magnetic beads.

(2) Requires very small amounts of target protein (only 30 micro-grams).

(3) Creates a diversified antibody-expressing cell library autonomously in vitro in an avian B-cell line (DT40) by activating recombination at the Ig locus.

(4) Allows for straight-forward humanization due to the very high homology between avian and human Ab sequences.

(5) Ab-expressing cells with high affinity to the target antigen can be selected and further proliferated within the ADLib® System to yield multiple potential pre-clinical candidates; and

(6) The ADLib® System has been successfully applied to difficult target antigens such as self/human/homologous antigens, GPCRs/trans-membrane proteins, sugars/lipids and haptens/small molecules.

Chiome also announced a new initiative to in-license novel Ab-addressable targets in exchange for access to its proprietary ADLib® libraries.

Preferred areas for collaboration are cancer, inflammatory/autoimmune and infectious diseases. These collaborative R&D partnerships are envisaged as 50:50 joint ventures where each side bears its own expenses and contributes equal effort, time and technology.

Academic researchers with novel and proprietary targets are also welcome as potential partners.

Finally, Chiome is pleased to announce its attendance at the following antibody conferences:

(1) Informa Life Sciences “Recombinant Antibodies” Conference 15-19 June 2009, Cologne, Germany http://www.iir-events.com/IIR-conf/LifeSciences/EventView.aspx?EventID=2176 (2) Terrapinn’s Americas Antibody Congress 2009 21-23 September 2009, Washington, DC http://www.terrapinn.com/2009/antibodyusa/ (3) GTCbio’s Antibody Partnering & Technology Summit 29-30 October 2009, San Francisco, Calif. http://www.gtcbio.com/Allconferences.aspx (4) CHI’s PEGS Summit Europe 06-08 October 2009, Exhibition Grounds, Hannover, Germany [held in conjunction with BioTechnica] http://www.pegsummiteurope.com 

To arrange a meeting at one of these conferences in advance, please contact the appropriate Chiome representative listed further below. We look forward to meeting you then.

About Chiome:

After receiving official authorization as a RIKEN Venture Enterprise, Chiome was established in February 2005 with the aim of commercializing the ADLib® System. The ADLib® System is a revolutionary technology that makes it possible to rapidly generate monoclonal antibodies in vitro by building highly diversified antibody-presenting, avian B-cell libraries by means of gene recombination. Since late 2005, Chiome has rapidly and successfully generated highly specific monoclonal antibodies using the ADLib® System that would not have been obtained using conventional methods. Company efforts are now being directed toward forming alliances with international pharma & biotech companies. Chiome has approximately 40 employees and has received significant venture funding from various well-known Japanese investment groups.